Pharmaceutical products

Tender description

NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B, cytokine modulatorsand other monoclonal antibodies, and fondaparinux. Offer reference number: CM/PHR/16/5527 CM/PHR/16/5527/01 — Tranche B: 1 March 2020 to 28 February 2022 with an option to extend (at the authority’s discretion)for a period or periods up to a total of 24 months. CM/PHR/16/5527/02 – Annual tranche — cytokine modulators and other monoclonal antibodies — 1 March 2020 to 28 February 2021 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months. CM/PHR/16/5527/03 – NHS framework agreement for Fondaparinux — London – 1 March 2020 – 31 August 2021, Southof England – 1 March 2020 – 31 August 2020, Midlands and East – 1 March 2020 – 28 February 2021, all with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/16/5527/01 — 1.3.2020 to 28.2.2022 – NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/16/5527/02 – 1 March 2020 to 28 February 2021 — NHS Framework for the NHS North of England Region, branded medicines – annual tranche — cytokine modulators and other monoclonal antibodies with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months. CM/PHR/16/5527/03 – NHS framework agreement for Fondaparinux — London – 1 March 2020 – 31 August 2021, with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months. South of England – 1 March 2020 – 31 August 2020, with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months. Midlands and East – 1 August 2020 – 28 February 2021, with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.